A Gamboa1,2, E Duaso3, P Marimón4, M Sandiumenge3, E Escalante3, C Lumbreras3, A Tarrida3. 1. Acute Geriatric Unit, Geriatric Service, Igualada Hospital, Igualada, Spain. agamboa@csa.cat. 2. Department of Geriatrics, Hospital de Igualada, Avenida Cataluña, 11, 08700, Igualada, Barcelona, Spain. agamboa@csa.cat. 3. Acute Geriatric Unit, Geriatric Service, Igualada Hospital, Igualada, Spain. 4. Acute Geriatric Unit, Traumatology and Orthopedic Surgery, Igualada Hospital, Igualada, Spain.
Abstract
A poorer functional status at the time of fracture is a predictor of non-adherence to oral bisphosphonates initiated after a hip fracture, and suggests further opportunities for optimization of secondary fracture prevention in this high-risk population. INTRODUCTION: Low adherence to treatment is a problem in post-fracture secondary prevention. We aimed to analyze the prognostic factors (related and predictive) associated with non-adherence to oral bisphosphonate prescription for hip fracture due to bone fragility (HFBF) 12 months after discharge from an acute geriatric unit. METHODS: Prospective study of bivariate data analyzing related and multivariate factors predicting non-adherence of oral bisphosphonates at 12 months after treatment for HFBF. The statistical study was performed with SPSS 19.0.0. RESULTS: We attended 368 patients with HFBF. At discharge, oral bisphosphonates were prescribed to 226 (61.42%) patients. At 12 months, we followed up 160 (70.7%) patients, 104 (65%) of whom had non-adherence to oral bisphosphonates. Bivariate analysis (adherent vs. non-adherent): age (83.79 ± 5.82 vs. 85.78 ± 5.80, p = .029); Lawton and Brody Index (4.29 ± 3.40 vs. 2.67 ± 3.31, p = .004); baseline Barthel Index (BI) (85.89 ± 21.99 vs. 74.18 ± 26.70) (p = .004); BI at admission (18.84 ± 10.00 vs. 14.47 ± 11.71, p = .004); BI at discharge (34.20 ± 15.40 vs. 27.45 ± 16.71, p = .011); baseline Functional Ambulation Classification (5.66 ± 0.98 vs. 5.43 ± 0.99, p = .025). Multivariate analysis: BI 0.980 (0.965-0.995, p = .007). Discriminatory capacity of the AUC model (± 95% CI): 0.634 (0.545-0.722). CONCLUSIONS: At 12 months, there was low adherence to treatment with oral bisphosphonates in our model. A lower BI prior to treatment is a predictive factor for non-adherence treatment with oral bisphosphonate.
A poorer functional status at the time of fracture is a predictor of non-adherence to oral bisphosphonates initiated after a hip fracture, and suggests further opportunities for optimization of secondary fracture prevention in this high-risk population. INTRODUCTION: Low adherence to treatment is a problem in post-fracture secondary prevention. We aimed to analyze the prognostic factors (related and predictive) associated with non-adherence to oral bisphosphonate prescription for hip fracture due to bone fragility (HFBF) 12 months after discharge from an acute geriatric unit. METHODS: Prospective study of bivariate data analyzing related and multivariate factors predicting non-adherence of oral bisphosphonates at 12 months after treatment for HFBF. The statistical study was performed with SPSS 19.0.0. RESULTS: We attended 368 patients with HFBF. At discharge, oral bisphosphonates were prescribed to 226 (61.42%) patients. At 12 months, we followed up 160 (70.7%) patients, 104 (65%) of whom had non-adherence to oral bisphosphonates. Bivariate analysis (adherent vs. non-adherent): age (83.79 ± 5.82 vs. 85.78 ± 5.80, p = .029); Lawton and Brody Index (4.29 ± 3.40 vs. 2.67 ± 3.31, p = .004); baseline Barthel Index (BI) (85.89 ± 21.99 vs. 74.18 ± 26.70) (p = .004); BI at admission (18.84 ± 10.00 vs. 14.47 ± 11.71, p = .004); BI at discharge (34.20 ± 15.40 vs. 27.45 ± 16.71, p = .011); baseline Functional Ambulation Classification (5.66 ± 0.98 vs. 5.43 ± 0.99, p = .025). Multivariate analysis: BI 0.980 (0.965-0.995, p = .007). Discriminatory capacity of the AUC model (± 95% CI): 0.634 (0.545-0.722). CONCLUSIONS: At 12 months, there was low adherence to treatment with oral bisphosphonates in our model. A lower BI prior to treatment is a predictive factor for non-adherence treatment with oral bisphosphonate.
Entities:
Keywords:
Adherence to oral bisphosphonates; Hip fracture due to fragility; Orthogeriatric; Osteoporosis; Secondary prevention
Authors: Anders Prestmo; Gunhild Hagen; Olav Sletvold; Jorunn L Helbostad; Pernille Thingstad; Kristin Taraldsen; Stian Lydersen; Vidar Halsteinli; Turi Saltnes; Sarah E Lamb; Lars G Johnsen; Ingvild Saltvedt Journal: Lancet Date: 2015-02-05 Impact factor: 79.321
Authors: A Naranjo; S Ojeda-Bruno; A Bilbao-Cantarero; J C Quevedo-Abeledo; B V Diaz-González; C Rodríguez-Lozano Journal: Osteoporos Int Date: 2015-06-06 Impact factor: 4.507
Authors: F Schaller; E Sidelnikov; R Theiler; A Egli; H B Staehelin; W Dick; B Dawson-Hughes; D Grob; A Platz; U Can; H A Bischoff-Ferrari Journal: Bone Date: 2012-06-12 Impact factor: 4.398
Authors: E C Folbert; J H Hegeman; M Vermeer; E M Regtuijt; D van der Velde; H J Ten Duis; J P Slaets Journal: Osteoporos Int Date: 2016-07-21 Impact factor: 4.507